Novel Therapeutics for Multiple Sclerosis Designed by Parasitic Worms

Area of Science:

• Immunology
• Evolutionary Biology
• Neuroimmunology

Background:

• Endemic helminth infections historically shaped a specific regulatory immune profile for tissue repair and parasite encapsulation.
• The "Old Friend's Hypothesis" suggests reduced helminth exposure in developed countries contributes to immune dysregulation and increased autoimmune diseases.
• Multiple Sclerosis (MS) prevalence inversely correlates with helminth infection rates globally.

Purpose of the Study:

• To explore the potential of helminth infections and their secreted molecules as therapeutic strategies for immune-mediated diseases, specifically Multiple Sclerosis.
• To investigate the link between diminished helminth exposure and the rising incidence of autoimmune disorders.

Main Methods:

• Review of epidemiological data correlating MS distribution with helminth prevalence.
• Analysis of studies on helminth infection in animal models of MS.
• Examination of findings from Phase 1 and 2 human clinical trials using helminth therapies for MS.

Main Results:

• A significant inverse correlation exists between global MS distribution and helminth infection prevalence.
• Animal models and early-phase human trials show promise for helminth infection as an MS treatment.
• Helminth-secreted immunomodulatory molecules present a potential alternative therapeutic avenue.

Conclusions:

• The evolutionary immune adaptations to helminths offer insights into immune-mediated diseases like MS.
• Helminth infection and its derived molecules represent a viable therapeutic strategy for MS, warranting further investigation.
• Targeting specific helminth molecules may provide a more refined approach to MS treatment than whole organism therapy.